Dianthus Therapeutics DNTH Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Liquidity | |||||
| Current ratio | 13.3×-1.9× | 15.2×-3.2× | 18.4×+8.5× | 10×-6.7× | |
| Quick ratio | 13.3×-1.9× | 15.2×-3.2× | 18.4×+8.5× | 10×-6.7× | |
| Cash ratio | 1.7×+0.4× | 1.2×-12.5× | 13.7×+11.9× | 1.9×-10.3× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×-0.4× | 0.4×— | |
| Valuation | |||||
| Market capitalization | $1.77B+174% | $645.21M+1,269% | $47.11M+96.7% | $23.95M-90.8% | |
| Enterprise value | $1.72B+175% | $623.91M+837% | -$84.63M-320% | $38.55M— | |
| Price / book | 3.6×+1.8× | 1.8×+1.6× | 0.3×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Dianthus Therapeutics's ratios come from?
- Every ratio is computed from Dianthus Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.